PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eszopiclone→

Eszopiclone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
138729-47-2
Molecular formula
C17H17ClN6O3
Molecular weight
388.8 g/mol
Drug class
Non-benzodiazepine hypnoticcyclopyrrolone ligand at the GABAA receptor complex
Mechanism of action
Interacts with GABAA receptor complexes at binding domains associated with benzodiazepine receptors, enhancing inhibitory neurotransmission. The precise mechanism by which eszopiclone produces hypnotic effects is not fully established.
Indications / reported uses
  • Treatment of insomnia characterised by difficulty with sleep onset and/or sleep maintenance in adults; use should be at the lowest effective dose and for the shortest clinically appropriate duration

Sources: US DailyMed — Eszopiclone · NLM MeSH — Eszopiclone · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Eszopiclone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eszopiclone Permitted Daily Exposure (PDE) report (the Eszopiclone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eszopiclone Occupational Exposure Limit (OEL) report (the Eszopiclone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.